Abstracts Archive - Page 171 of 2607 - ACR Meeting Abstracts

Abstract Number: 0684 • ACR Convergence 2025
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
Antonia Valenzuela¹, Adriana Miguel Alvarez², Patricia E. Carreira³, Alejandra Babini⁴, Diana Rocío Gil Calderón⁵, John Pauling⁶ and Tatiana Rodriguez-Reyna², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁴Hospital Italiano, Córdoba, Argentina, ⁵Hospital Universitario Mayor MEDERI, Universidad del Rosario, Artmedica SAS, Bogotá, Colombia, ⁶North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 0067 • ACR Convergence 2025
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Amara Seng¹, Kensuke Suga², Diana Tran³, Anvita Singaraju⁴, Tanyalak Parimon⁵, Youn Jung Choi⁶, Justyna Fert-Bober⁷, Jon Giles⁸, Peter Chen⁵ and Nunzio Bottini⁹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ³Cedars Sinai Medical Center, La Cañada Flintridge, CA, ⁴Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, ⁵Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, Los Angeles, CA, ⁹Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Symptomatic rheumatoid arthritis-related interstitial lung disease (RA-ILD) is prevalent in about 10% of patients with RA and confers a higher mortality compared with RA…
Abstract Number: 0530 • ACR Convergence 2025
Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
Annika Nack¹, Xabier Michelena Vegas², Pol Maymó-Paituvi³, Cristina Calomarde-Gómez⁴, david lobo⁵, Asier García-Alija⁶, Raquel Ugena-García⁴, Maria Aparicio¹, Paola Vidal Montal⁷ and Diego Benavent⁸, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Universitari Vall Hebron, Barcelona, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Doctor Josep Trueta University Hospital, Girona, Catalonia, Spain, ⁶Sant Pau Hospital, Barcelona, Catalonia, Spain, ⁷Bellvitge University Hospital, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, Madrid, Spain
Background/Purpose: Low back pain (LBP) is a multifactorial condition managed by various specialists. AI chatbots like ChatGPT may help clinicians identify probable diagnoses. Given that…
Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Nicholas Bauer¹, Rufei Lu¹, Carla Guthridge¹, Tayte Stephens², Benjamin Jones³, Wade DeJager⁴, Susan Macwana¹, Caroline Shiboski⁵, Alan Baer⁶, Christopher Lessard¹, Astrid Rasmussen¹, Stephen Shiboski⁵, Judith James¹, Linda F. Thompson¹, Blake M. Warner⁷, A. Darise Farris¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma State University, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵University of California San Francisco, San Francisco, CA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…
Abstract Number: 0687 • ACR Convergence 2025
Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Arjun Mahajan¹, Nikki Zangenah², Maria Vazquez-Machado², Avery LaChance³ and Jeffrey Sparks⁴, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic sclerosis (SSc) face increased cancer risk compared to the general population, yet current evidence on specific cancer patterns and their relationship…
Abstract Number: 0535 • ACR Convergence 2025
Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Chamaida Plasencia-Rodríguez⁴, Alejandro Balsa⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, MADRID, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Inflammatory back pain (IBP) is very relevant for identifying patients at risk of axial spondyloarthritis (axSpA). Mounting evidence has indicated substantial variability in sensitivity…
Abstract Number: 1026 • ACR Convergence 2025
Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
Naomi Schlesinger¹ and Ioannis Androulakis², ¹Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ²Rutgers University, Piscataway, NJ
Background/Purpose: Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: 1110 • ACR Convergence 2025
Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Madalyn Walsh¹, Jeremy Zhang², Bashar Abuqayas¹, Sanchay Jain³, Yosef Zakharia⁴, Aleksander Lenert⁵ and Jennifer Strouse⁶, ¹University of Iowa Hospitals & Clinics, Iowa City, IA, ²Rush University, Chicago, IL, ³University of Iowa, Iowa City, IA, ⁴Mayo Clinic, Rochester, MN, ⁵Iowa Carver College of Medicine, Iowa City, IA, ⁶University of Iowa, Iowa City
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of an increasing number of malignancies. Because patients with pre-existing autoimmune disease have been excluded from…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…
Abstract Number: 1114 • ACR Convergence 2025
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Mei-Feng Shi¹, Fang-Shu Zou¹, Xiao-Na Ma¹, Wei Feng¹, Yi-Fang Zhang², Chang-Song Lin¹, Min-Ying Liu² and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].